Bora Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
Bora Pharmaceuticals has been growing earnings at an average annual rate of 48.8%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually. Revenues have been growing at an average rate of 47.1% per year. Bora Pharmaceuticals's return on equity is 28.7%, and it has net margins of 23.3%.
Key information
48.8%
Earnings growth rate
47.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | 47.1% |
| Return on equity | 28.7% |
| Net Margin | 23.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Bora Pharmaceuticals' (TWSE:6472) Earnings Are Weaker Than They Seem
Nov 21
Does Bora Pharmaceuticals (TWSE:6472) Deserve A Spot On Your Watchlist?
Oct 04Investors Appear Satisfied With Bora Pharmaceuticals Co., LTD.'s (TWSE:6472) Prospects
Jul 18Is Bora Pharmaceuticals Co., LTD. (TWSE:6472) Trading At A 44% Discount?
Jun 13Bora Pharmaceuticals Co., LTD. (TWSE:6472) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected
Apr 10Bora Pharmaceuticals (TWSE:6472) Could Easily Take On More Debt
Apr 08Shareholders Can Be Confident That Bora Pharmaceuticals' (TWSE:6472) Earnings Are High Quality
Mar 14Is Bora Pharmaceuticals (GTSM:6472) A Risky Investment?
Apr 30Are Strong Financial Prospects The Force That Is Driving The Momentum In Bora Pharmaceuticals Co., LTD.'s GTSM:6472) Stock?
Mar 17Bora Pharmaceuticals (GTSM:6472) Has Rewarded Shareholders With An Exceptional 695% Total Return On Their Investment
Feb 17
New Forecasts: Here's What Analysts Think The Future Holds For Bora Pharmaceuticals Co., LTD. (GTSM:6472)
Jan 27Bora Pharmaceuticals (GTSM:6472) Takes On Some Risk With Its Use Of Debt
Jan 19We're Not So Sure You Should Rely on Bora Pharmaceuticals's (GTSM:6472) Statutory Earnings
Dec 29Are Robust Financials Driving The Recent Rally In Bora Pharmaceuticals Co., LTD.'s (GTSM:6472) Stock?
Dec 09Revenue & Expenses Breakdown
How Bora Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 16,705 | 3,900 | 2,977 | 565 |
| 30 Jun 24 | 14,166 | 3,187 | 2,347 | 462 |
| 31 Mar 24 | 12,277 | 2,707 | 1,641 | 336 |
| 31 Dec 23 | 14,200 | 3,030 | 1,444 | 298 |
| 30 Sep 23 | 16,293 | 2,868 | 1,344 | 272 |
| 30 Jun 23 | 15,942 | 2,704 | 1,212 | 238 |
| 31 Mar 23 | 14,158 | 2,252 | 1,056 | 176 |
| 31 Dec 22 | 10,494 | 1,392 | 862 | 129 |
| 30 Sep 22 | 6,346 | 1,128 | 687 | 57 |
| 30 Jun 22 | 4,811 | 697 | 586 | 38 |
| 31 Mar 22 | 4,650 | 594 | 571 | 41 |
| 31 Dec 21 | 4,900 | 750 | 585 | 41 |
| 30 Sep 21 | 4,418 | 1,045 | 637 | 40 |
| 30 Jun 21 | 3,626 | 963 | 578 | 39 |
| 31 Mar 21 | 2,794 | 868 | 507 | 37 |
| 31 Dec 20 | 1,800 | 578 | 441 | 37 |
| 30 Sep 20 | 1,523 | 191 | 300 | 37 |
| 30 Jun 20 | 1,513 | 232 | 293 | 38 |
| 31 Mar 20 | 1,521 | 262 | 280 | 39 |
| 31 Dec 19 | 1,529 | 305 | 259 | 40 |
| 30 Sep 19 | 1,517 | 355 | 217 | 38 |
| 30 Jun 19 | 1,492 | 283 | 236 | 41 |
| 31 Mar 19 | 1,515 | 267 | 227 | 41 |
| 31 Dec 18 | 1,372 | 443 | 220 | 38 |
| 30 Sep 18 | 1,107 | 351 | 200 | 36 |
| 30 Jun 18 | 846 | 330 | 141 | 28 |
| 31 Mar 18 | 525 | 274 | 116 | 23 |
| 31 Dec 17 | 358 | 14 | 87 | 20 |
| 30 Sep 17 | 323 | 17 | 81 | 19 |
| 30 Jun 17 | 297 | 22 | 74 | 18 |
| 31 Mar 17 | 291 | 24 | 73 | 18 |
| 31 Dec 16 | 283 | 25 | 71 | 18 |
| 30 Sep 16 | 273 | 23 | 68 | 18 |
| 30 Jun 16 | 260 | 18 | 69 | 18 |
| 31 Mar 16 | 247 | 26 | 67 | 17 |
| 31 Dec 15 | 238 | 34 | 65 | 17 |
| 30 Sep 15 | 236 | 30 | 65 | 13 |
| 30 Jun 15 | 234 | 28 | 68 | 12 |
| 31 Mar 15 | 226 | 23 | 65 | 10 |
| 31 Dec 14 | 218 | 17 | 62 | 9 |
| 30 Sep 14 | 182 | 16 | 54 | 9 |
| 30 Jun 14 | 154 | 16 | 44 | 8 |
| 31 Mar 14 | 123 | 10 | 41 | 6 |
| 31 Dec 13 | 93 | 4 | 37 | 3 |
Quality Earnings: 6472 has a large one-off gain of NT$1.3B impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 6472's current net profit margins (23.3%) are higher than last year (17.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6472's earnings have grown significantly by 48.8% per year over the past 5 years.
Accelerating Growth: 6472's earnings growth over the past year (36%) is below its 5-year average (48.8% per year).
Earnings vs Industry: 6472 earnings growth over the past year (36%) exceeded the Pharmaceuticals industry 11.9%.
Return on Equity
High ROE: Whilst 6472's Return on Equity (28.66%) is high, this metric is skewed due to their high level of debt.